Home/Filings/4/0001562180-19-006220
4//SEC Filing

DAVIS JOHN C. JR 4

Accession 0001562180-19-006220

CIK 0001690585other

Filed

Dec 19, 7:00 PM ET

Accepted

Dec 20, 5:52 PM ET

Size

12.2 KB

Accession

0001562180-19-006220

Insider Transaction Report

Form 4
Period: 2019-12-20
DAVIS JOHN C. JR
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2019-12-20$9.49/sh+114$1,0828,418 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-12-20805236,239 total
    Exercise: $9.49Exp: 2028-04-25Common Stock (805 underlying)
  • Exercise/Conversion

    Common Stock

    2019-12-20$9.49/sh+805$7,6399,223 total
  • Sale

    Common Stock

    2019-12-20$15.00/sh919$13,7858,304 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-12-20114236,125 total
    Exercise: $9.49Exp: 2028-04-25Common Stock (114 underlying)
Footnotes (2)
  • [F1]This trade is pursuant to an active 10b5-1 plan.
  • [F2]25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

Issuer

Magenta Therapeutics, Inc.

CIK 0001690585

Entity typeother

Related Parties

1
  • filerCIK 0001741287

Filing Metadata

Form type
4
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 5:52 PM ET
Size
12.2 KB